Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767493 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
A Phase 4 study of Multiple Sclerosis, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01767493 is a Phase 4 study of Multiple Sclerosis that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 19 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01767493, a Phase 4 study of Multiple Sclerosis, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
Conditions Studied
Interventions
- DRUG [18F]Florbetapir PET imaging
Study Locations (1)
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767493
The ClinicalTrials.gov registry entry for NCT01767493 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which [18F]Florbetapir PET imaging is the first listed.
NCT01767493 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01767493 about?
NCT01767493 is a clinical study titled "Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients". The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
What is the current status of trial NCT01767493?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2012-11. Estimated completion is 2013-11.
What conditions does trial NCT01767493 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01767493?
The interventions under investigation include: [18F]Florbetapir PET imaging (DRUG).
Who is sponsoring clinical trial NCT01767493?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01767493 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Home Based Infusions for Ocrelizumab
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.